Abstract
Anti-Hu paraneoplastic syndromes are usually associated with an underlying neoplasia, although a few patients who are anti-Hu-positive never develop cancer after long-term follow-up. Tumour therapy remains the mainstay of therapeutic options, and early immune therapy in parallel is advisable. When no tumour is found, immunologically-based therapies are nowadays the only options. Recent studies have shown rituximab associated with the tumour therapy to be effective for some patients with anti-Hu paraneoplastic syndrome. We report a case of a patient with anti-Hu antibodies-associated sensory neuronopathy and gastric pseudo-obstruction without an underlying neoplasia four years after the first manifestation who has achieved sustained improvement for two years after treatment with rituximab. This case report supports the effectiveness of rituximab in these syndromes, even for cases where no underlying neoplasia is demonstrated. Further studies are warranted in order to confirm these preliminary data.
References
Graus F, Keime-Guibert F, Reñe R et al (2001) Anti-Hu-associated paraneoplastic encephalomyelitis: analysis of 200 patients. Brain 124:1138–1148. doi:10.1093/brain/124.6.1138
Lladó A, Carpentier AF, Honnorat J et al (2006) Hu-antibody-positive patients with or without cancer have similar clinical profiles. J Neurol Neurosurg Psychiatry 77:996–997. doi:10.1136/jnnp.2005.085753
Szabo A, Dalmau J, Manley G et al (1991) HuD, a paraneoplastic encephalomyelitis antigen, contains RNA-binding domains and is homologous to Elav and Sex-lethal. Cell 67:325–333. doi:10.1016/0092-8674(91)90184-Z
Honnorat J, Cartalat-Carel S (2004) Advances in paraneoplastic neurological syndromes. Curr Opin Oncol 16:614–620. doi:10.1097/01.cco.0000142486.89472.eb
Esposito M, Penza P, Orefice G et al (2008) Successful treatment of paraneoplastic cerebellar degeneration with Rituximab. J Neurooncol 86:363–364. doi:10.1007/s11060-007-9479-z
Shams’ili S, Beukelaar J, Willem Gratama J et al (2006) An uncontrolled trial of rituximab for antibody associated paraneoplastic neurological syndromes. J Neurol 253:16–20. doi:10.1007/s00415-005-0882-0
Byrne T, Mason WP, Posner JB, Dalmau J (1997) Spontaneous neurological improvement in anti-Hu associated encephalomyelitis. J Neurol Neurosurg Psychiatry 62:276–278. doi:10.1136/jnnp.62.3.276
Lladó A, Mannucci P, Carpentier AF et al (2004) Value of Hu antibody determinations in the follow-up of paraneoplastic neurologic syndromes. Neurology 63:1947–1949
Darnell JC, Posner JB (2003) Paraneoplastic syndromes involving the nervous system. N Engl J Med 349:1543–1554. doi:10.1056/NEJMra023009
Graus F, Illa I, Agusti M, Ribalta T et al (1991) Effect of intraventricular injection of an anti-Purkinje cell antibody (anti-Yo) in a guinea pig model. J Neurol Sci 106:82–87. doi:10.1016/0022-510X(91)90198-G
Gonzalez-Stawinski GV, Yu PB, Love SD et al (2001) Hapten-induced primary and memory humoral responses are inhibited by the infusion of anti-CD20 monoclonal antibody. Clin Immunol 98:175–179. doi:10.1006/clim.2000.4980
Arzoo K, Sadeghi S, Liebman HA (2002) Treatment of refractory antibody mediated autoimmune disorders with an anti-CD20 monoclonal antibody (rituximab). Ann Rheum Dis 61:922–924. doi:10.1136/ard.61.10.922
Graus F, Dalmau J (2007) Paraneoplastic neurological syndromes: diagnosis and treatment. Curr Opin Neurol 20:732–737
Acknowledgements
The authors wish to thank Dr Graus (Neurology Service, Hospital Clinic, Barcelona) for performing the antineuronal antibodies determination.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Coret, F., Bosca, I., Fratalia, L. et al. Long-lasting remission after rituximab treatment in a case of anti-Hu-associated sensory neuronopathy and gastric pseudoobstruction. J Neurooncol 93, 421–423 (2009). https://doi.org/10.1007/s11060-008-9787-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11060-008-9787-y